Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.This is
Health Canada has issued a warning that mixing some slow-release painkillers with alcohol could be potentially deadly. The drugs, known as opioids, are often used to relieve severe pain over a
Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development. The compound,
Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Diovan (valsartan), the most prescribed ARB (angiotensin receptor blocker) in the US and w
PRB Pharmaceuticals and Lee's Pharmaceuticals have announced that a recent study by Taiwan researchers from the National Health Researc
Scientists are apparently working on producing a vaccine that could give lifelong protection against all types of flu in one single injection. During a flu outbreak the most at risk people are the elderly and those who are sick, and they need a
Pharmaceutical companies in the United States are up in arms over plans by U.S. regulators to release preliminary information, about the potential side effects of drugs.The drug manufacturers say that the action could lead to unnecessary confus
Quintiles Transnational Corp. today announced an agreement to conduct clinical trials in Peru involving ethnic Japanese, further expanding the company's ability to support new drug applications in Japan
Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV). The Phase 2 study is a three-arm, double-blind
Apparently federal health officials will soon decide whether to allow the sale of emergency contraception without a prescription.Despite some quite aggressive attempts to restrict it's availability, some states are already are preparing to expa
The complaint was filed with South Africa's Competition Tribunal in August by AIDS Healthcare Foundation (AHF), the US' largest AIDS organization and several other South African AIDS advocates. AHF operates the 'Ithembalabantu' (Zulu for people's hope) clinic, a free AIDS treatment clinic in Umlazi Township, KwaZulu Natal in partnership with the Network of AIDS Communities of South Africa (NetCom SA) a local non-government organization. In the complaint, AHF and others allege that GSK has charged excessive prices for AIDS drugs to the detriment of South Africans with HIV/AIDS and in violation of the Competition Act.
"Like most bullies, GSK was full of bluster when it vowed repeatedly that it would appeal the very filing of our Tribunal Complaint," said Michael Weinstein, AHF's president. "Yet last week, GSK instead merely filed a response in South Africa by the required deadline. And in its response, GSK hides behind a wall of lawyers and legal arguments, attempting to assert technicalities as to why the Tribunal should not hear this case. If, as GSK claims, it's done nothing wrong, it should be spending its time showing the world why, how -- or even if -- GSK did not violate the law with its AIDS drug pricing in South Africa. Apparently, GSK has to charge illegally high prices so it can pay for its lawyers."
GSK's response to the complaint is the latest step in the ongoing case. The complaint was originally filed with the Competition Commission in January 2003. The Treatment Action Campaign (TAC) had lodged a similar complaint with the Competition Commission against GSK during 2002. The Competition Commission initially decided to refer that complaint, as well as the AHF complaint, to the Competition Tribunal. During December 2003, TAC and GSK concluded a settlement endorsed by the Competition Commission; however, AHF was not a party to that settlement.
Earlier this summer, the Competition Tribunal of South Africa agreed to hear the complaint, which was filed by individual South Africans and AHF. The Tribunal also ordered GSK to pay AHF's legal costs.
"The voices of the Complainants and the patients AHF treats were not heard in the other case, and were not included in the settlement. Now, they will be heard," said AHF's Weinstein, expressing his gratitude for the Tribunal's actions.
The case name is In The Matter Between Mpho Makhathnini, Nelislwe Mthethwa, Musa Msomi, Elijah Paul Musoke, Tom Myers, AIDS Healthcare Foundation Limited, and GlaxoSmithKline (Pty) Ltd, Glaxo Group Limited, Case Number 34/CR/Apr04.
http://www.aidshealth.org/